Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos

The proposed UK divestiture is intended to avoid a Phase 2 investigation, while the expected cost savings remain unchanged.

Rhea-AI Summary

Brink's (BCO) received the UK Competition and Markets Authority's acceptance in principle of a proposed remedy for its planned NCR Atleos acquisition.

The remedy involves divesting NoteMachine/TestLink UK to address UK-specific competition concerns and avoid referral to a Phase 2 investigation. The sale process is progressing, with Brink's engaged with several prospective buyers; selecting a suitable buyer and completing the divestiture remain outstanding.

Brink's expects the acquisition of NCR Atleos (NATL) to close early in the first quarter of 2027 and continues to expect $200 million in annual run-rate cost synergies, or annualized cost savings, within three years of closing. The potential divestiture was contemplated in previously disclosed financial metrics and does not change that savings expectation.

3 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointCMA acceptance in principle advances Brink's proposed remedy for the NCR Atleos acquisition.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Brink's continues to expect $200 million in annual run-rate cost synergies within three years of closing.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Acquisition remains on track, with Brink's expecting closing early in the first quarter of 2027.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed NoteMachine/TestLink UK divestiture still requires a suitable buyer and timely completion to avoid Phase 2 referral.

Key Figures

Annual run-rate cost synergies: $200 million annually Expected acquisition closing: Early in the first quarter of 2027

Annual run-rate cost synergies

$200 million annually

Expected within three years of closing; company says the proposed UK sale does not affect this expectation

Expected acquisition closing

Early in the first quarter of 2027

Brink’s says the NCR Atleos acquisition remains on track

Previous Acquisition Reports

2 past events · Latest: Jun 30

Same Type 2 events

1. Jun 30

   Shareholder approval

   24h Move

   +2.5%

   Shareholders approved the NCR Atleos acquisition; HSR clearance had been received.

2. Feb 26

   Acquisition announcement

   24h Move

   -13.9%

   Brink’s announced the $6.6 billion NCR Atleos deal and projected $200 million annual synergies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

undertaking in lieu, phase 2 investigation, run-rate

3 terms

undertaking in lieu regulatory

"an acceptable remedy (or "undertaking in lieu" of a referral"

A written, voluntary promise submitted to a regulator, court, or other authority to do (or stop doing) specified actions instead of that authority issuing a formal order, penalty, or pursuing enforcement proceedings. It is a binding commitment while in force, usually sets specific actions and timeframes, and can be enforced by the authority that accepted it (for example through contempt, breach remedies, or conversion into a formal order); it does not automatically carry the same legal precedents or statutory consequences as a full adjudication unless the accepting body treats it otherwise.

phase 2 investigation regulatory

"a referral for a Phase 2 investigation"

A Phase 2 investigation is a mid-stage clinical trial required in the drug or medical-device approval process that tests whether a treatment has the intended biological effect and acceptable short-term safety in patients with the target condition. It typically enrolls more participants than Phase 1, often uses control groups or dose-ranging arms, and produces the preliminary efficacy data and dosing information regulators and developers use to decide whether to proceed to larger, definitive Phase 3 trials; it does not by itself provide the broad safety and efficacy evidence needed for regulatory approval.

run-rate financial

"$200 million in annual run-rate cost synergies"

Run-rate is an estimate of a company’s future annual performance created by multiplying recent results (such as a month or quarter) to project a full year, like using current speed to guess how far you’ll travel in a year. Investors use it as a quick way to gauge growth, size and momentum and to compare firms, but it can be misleading if recent results include one-time events or seasonal swings, so it’s a rough, not definitive, forecast.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Divestiture of NoteMachine/TestLink UK to avoid a CMA Phase 2 referral

Acquisition of NCR Atleos remains on track to close early in the first quarter of 2027

RICHMOND, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- The Brink's Company (NYSE: BCO) (“Brink’s” or “the Company”) announced today that the United Kingdom's Competition and Markets Authority ("CMA") has accepted in principle Brink’s proposed remedy for its planned acquisition of NCR Atleos Corporation (NYSE: NATL) (“NCR Atleos”).

Brink's has been working constructively with the CMA to establish that the divestiture of NoteMachine/TestLink UK is an acceptable remedy (or "undertaking in lieu" of a referral for a Phase 2 investigation) to address the UK-specific concerns that the CMA shared with Brink’s early in the review process. Brink’s is committed to selecting a suitable buyer and concluding the divestiture process in a timely manner in order to avoid the CMA referring the acquisition to a Phase 2 investigation. As previously announced on September 30, 2026, the sale process is progressing, and Brink’s remains engaged with a number of prospective buyers.

"We are pleased with the CMA’s acceptance in principle of the proposed remedy, as this represents a significant step forward, and we appreciate the CMA's constructive and timely engagement throughout the process," said Mark Eubanks, President and Chief Executive Officer of Brink's. "The potential sale of NoteMachine/TestLink UK was a remedy that was contemplated in the financial metrics that Brink’s has previously disclosed and does not impact the $200 million in annual run-rate cost synergies that we continue to expect to achieve within three years of closing the transaction. We continue to make progress towards the successful completion of our pending acquisition of NCR Atleos and look forward to positioning the combined business to deliver enhanced customer solutions and accelerate our value creation strategy."

Brink's acquisition of NCR Atleos remains on track to close early in the first quarter of 2027.

About The Brink’s Company 
The Brink’s Company (NYSE: BCO) is a leading global provider of cash and valuables management, digital retail solutions, and ATM managed services. Our customers include financial institutions, retailers, government agencies, mints, jewelers and other commercial operations. Our network of operations in 51 countries serves customers in more than 100 countries. For more information, please visit our website at www.brinks.com. 

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “assume,” “can,” “could,” “estimate,” “expect,” “target,” “possible,” “project,” “predict,” “intend,” “plan,” “believe,” “potential,” “may,” “should”, “will” and similar expressions are based on current expectations and assumptions and are subject to risks, uncertainties and contingencies, many of which are beyond our control and difficult to predict or quantify, and which could cause actual results to differ materially from those that are anticipated.

Factors that could cause actual results to differ include, but are not limited to: Brink’s ability to consummate the acquisition of NCR Atleos (the “Transaction”); the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement with respect to the Transaction; Brink’s ability to finance the Transaction; Brink’s indebtedness, including the substantial indebtedness Brink’s will incur in connection with the Transaction and the need to generate sufficient cash flows to service and repay such indebtedness; failure to consummate any anticipated repayment of the combined company’s indebtedness or make any returns to shareholders in the expected timeframe or at all; failure to obtain applicable regulatory approvals in a timely manner or otherwise; failure to satisfy any other conditions to closing of the Transaction; failure to realize the anticipated benefits and synergies of the Transaction in the expected timeframe or at all, including as a result of a delay in consummating the Transaction; the success of integration plans and the time required to successfully integrate NCR Atleos’ operations with those of Brink’s; the focus of management’s time and attention on the Transaction and other potential disruptions arising from the Transaction; the effects of the announcement of the Transaction on Brink’s or NCR Atleos’ businesses; that operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with banks, employees, customers or suppliers) may be greater than expected following the public announcement of the Transaction; Brink’s or NCR Atleos’ ability to retain certain key employees following the public announcement of the Transaction; litigation related to the Transaction; Brink’s or NCR Atleos’ ability to obtain certain third party or governmental regulatory consents, approvals or clearances; potential undisclosed liabilities of NCR Atleos not identified during the due diligence process; the impact of the Transaction on the market price of Brink’s or NCR Atleos’ common stock and/or operating results; and general economic conditions that are less favorable than expected.

Additional information concerning other risk factors is also contained in Part I, Item 1A “Risk Factors” of (i) Brink’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, and (ii) NCR Atleos’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 27, 2026 and, in each case, in subsequent filings with the SEC.

The forward-looking information included in this press release is representative only as of the date of the communications included in this press release and Brink’s and NCR Atleos undertake no obligation to update, revise or clarify any information contained in this press release or forward-looking statements that may be made from time to time on either of their behalf, whether as a result of new information, future events or otherwise, except as required by law.

Contacts 
Investor Inquiries 
Jesse Jenkins 
jesse.jenkins@brinksinc.com 

Media Inquiries 
Kelly McNeff 
(469) 549-6555 
brinksmedia@brinks.com 

OR 

FGS Global 
brinks@fgsglobal.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What remedy has the CMA accepted in principle for Brink's acquisition of NCR Atleos?

The CMA has accepted in principle Brink's proposed divestiture of NoteMachine/TestLink UK. The remedy addresses UK-specific competition concerns and is intended to avoid referral to a Phase 2 investigation. Brink's remains engaged with prospective buyers.

When does Brink's expect to close its acquisition of NCR Atleos?

Brink's expects the acquisition to close early in the first quarter of 2027. The transaction remains pending, and the proposed UK divestiture has received CMA acceptance in principle.